prod:prod_dcx-login
Xpert® Xpress CoV-2/Flu/RSV plus
Actionable rapid respiratory results to meet the challenges of co-circulating respiratory viruses
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
XP3COV2/FLU/RSV-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Copan 305CN (Nasopharyngeal Swab)
305C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Copan 346N (Nasal Swab)
346C
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- Rapidly detect SARS-CoV-2, including emerging variants, to provide timely and effective results
- Accurately detect respiratory tract infections to ensure appropriate patient treatment
- Differentiate Flu A, Flu B, RSV, and CoV-2 along with potential co-infections during the respiratory season
Full test runtime is 36 minutes. SARS-CoV-2 positive results available in as soon as 25 minutes with early assay termination.
The Solution
- Actionable detection of SARS-CoV-2 in as little as 25 minutes, with results for all four pathogens in just 36 minutes
- Robust design with multiple gene targets offers broader coverage to mutations
- Rapid sample to answer provides actionable results from a single sample with less than one minute of hands-on time
- Standardization of results by running the same assay in the central lab and decentralized testing sites
The Impact
- Ensures that patients receive appropriate treatment in a timely manner
- Supports clinicians with broader coverage for CoV-2 variants and Flu mutations
- Single cartridge with an easy-to-use workflow, enabling hospitals to effectively manage limited resources
In the United States: This test has not been FDA cleared or approved. This tests has been authorized by FDA under an EUA for use by authorized laboratories. Xpert Xpress CoV-2/Flu/RSV plus has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.